Claudio C.
- Country
- Italy
- Department
- Unità di Ematologia
Research Overview
- Phase 1 Evaluation of GSK2857916 Combined with Standard of Care in Newly Diagnosed Multiple Myeloma Patients
- Safety Evaluation of CC-93269 in Patients with Relapsed and Refractory Multiple Myeloma
- Pharmacokinetic Comparability Study of Pre- and Post-change Teclistamab in Relapsed/Refractory Multiple Myeloma Patients
Data & Insights
Has run more than one trial at 208 of 356 partner sites.
Specializations
Multiple Myeloma Treatment
Specializes in evaluating novel therapeutic approaches for multiple myeloma, with particular focus on investigating innovative treatment combinations and emerging therapies for both newly diagnosed and relapsed/refractory cases.
- Novel therapeutic agents
- Combination therapy assessment
- Treatment resistance management
Actively involved in research of bispecific antibodies and targeted therapies including elranatamab, teclistamab, and linvoseltamab.
Early Disease Intervention
Focuses on early intervention strategies for high-risk smoldering multiple myeloma and monoclonal gammopathy of undetermined significance, exploring preventive therapeutic approaches.
- Disease progression prevention
- Early-stage treatment optimization
- Risk stratification approaches
Investigates innovative treatment protocols for pre-malignant plasma cell disorders.
Hematologic Malignancies
Conducts research in various blood cancers, including acute myeloid leukemia and myelodysplastic syndrome, exploring novel therapeutic combinations and treatment strategies.
- Advanced treatment protocols
- Drug resistance mechanisms
- Therapeutic innovation
Evaluates emerging compounds and combination approaches for blood disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.